OGN

Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity

Retrieved on: 
Wednesday, February 2, 2022
Health, Consumer, Women, Other Health, Managed Care, Pharmaceutical, Biotechnology, MSD, Awareness, MRK, OGN, Organization, International Women's Health Coalition, Woman, Research, COVID-19, HealthyWomen, International, Workplace, Mental health, Health, Ageing, Investment, Family, Movement, IWD, NYSE, Parity, Pharmaceutical industry, Organon, Merck

The company invites organizations across the globe to join in raising awareness of the inequity in womens health and to adopt initiatives that help women prioritize their health.

Key Points: 
  • The company invites organizations across the globe to join in raising awareness of the inequity in womens health and to adopt initiatives that help women prioritize their health.
  • Women have worked hard to advance in the workplace, but the pandemic is unraveling these hard-fought gains.
  • We believe that by improving the understanding of womens health needs, we are one step closer to closing the inequity gap.
  • In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022

Retrieved on: 
Tuesday, February 1, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Managed Care, MSD, EST, Webcast, MRK, Investment, OGN, NYSE, Interest, Health, Woman, ID, Merck, Organon

Organon (NYSE: OGN), will release its fourth quarter and full year 2021 financial results on February 17, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), will release its fourth quarter and full year 2021 financial results on February 17, 2022, prior to the companys webcast and conference call scheduled for 8:30 a.m. EST.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the companys website.
  • Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 2682555 and by clicking on this link: http://www.directeventreg.com/registration/event/2682555 .

FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, MSD, Safety, COVID-19, View, Gastroenterology, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Endocrinology, MRK, Review, Forward-looking statement, Ophthalmology, Pharmacokinetics, NYSE, AbbVie, Social media, U.S. Securities and Exchange Commission, Twitter, Security (finance), OGN, Health, SEC, LinkedIn, FDA, Woman, Private Securities Litigation Reform Act, Patent, Hematology, Form 10-K, News, Multimedia, SB5, Investment, Pharmaceutical industry, Organon, Merck

The low concentration and high concentration forms of the reference product are both marketed in the United States (U.S.) today.

Key Points: 
  • The low concentration and high concentration forms of the reference product are both marketed in the United States (U.S.) today.
  • Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone.
  • Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company.
  • Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology.

Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference

Retrieved on: 
Monday, December 20, 2021
Biotechnology, Women, Consumer, Health, Pharmaceutical, MSD, Investment, NYSE, Conference, MRK, Woman, OGN, Health, Merck, Organon

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on Monday, January 10, 2022 at 2:15 p.m.

Key Points: 
  • Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on Monday, January 10, 2022 at 2:15 p.m.
  • Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives.
  • Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon Completes Acquisition of Forendo Pharma

Retrieved on: 
Monday, December 13, 2021
Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Forward-looking statement, U.S. Securities and Exchange Commission, Security (finance), Lead, Company, Physician, Patent, NYSE, Private Securities Litigation Reform Act, MRK, Industry, Woman, Seed, COVID-19, Acquisition, Research and development, HSD17B1, SEC, Chronic liver disease, Endometriosis, Moelis & Company, Novartis, OGN, Tissue, Achievement, Prevalence, Investment, Anovulation, Intracrine, Form 10-K, HSD17B, PCOS, News, Health, Pharmaceutical industry, Risk management, Merck, Organon, Organon, Forendo, ORGANON, FORENDO

Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.
  • Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • These statements include statements about the acquisition of Forendo and the potential for innovation and future treatment options.
  • Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference

Retrieved on: 
Monday, November 22, 2021
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, MSD, Woman, Evercore, Health, Investment, MRK, Conference, OGN, NYSE

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021 at 1:50 p.m.

Key Points: 
  • Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021 at 1:50 p.m.
  • Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
  • Organon has a global footprint that serves people in over 140 markets, world-class commercial capabilities and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee Experiences

Retrieved on: 
Wednesday, November 17, 2021
Data Management, Health, Technology, Software, General Health, Networks, Patient, Automation, Adoption, Interactivity, Technology, Private Securities Litigation Reform Act, OGN, NYSE, Signals intelligence operational platforms by nation, 2009 Davis Cup, SE, VP, Annual report, SAP SE, U.S. Securities and Exchange Commission, SAP, Form 20-F, ERP, Knowledge, Instagram, Advanced technology, LinkedIn, Multimedia, Growth, AWS, Â, Operation, Risk management, Online shopping, Sales

Accenture (NYSE: ACN) has been selected by Organon (NYSE: OGN), a global health care company, to help establish and manage the transformation of the companys enterprise resource planning (ERP) technology into a cloud-based digital core that will improve patient and employee experiences.

Key Points: 
  • Accenture (NYSE: ACN) has been selected by Organon (NYSE: OGN), a global health care company, to help establish and manage the transformation of the companys enterprise resource planning (ERP) technology into a cloud-based digital core that will improve patient and employee experiences.
  • Accenture will deploy the solution using AWS cloud hosting for scalability and a faster implementation time, leveraging the jointly developed accelerators with AWS via the Accenture AWS Business Group .
  • Additionally, Organon will use Accenture myConcerto to identify business challenges, define a transformation vision and build a value case that guides its roadmap development, delivery, change management and underpins continuous innovation.
  • Blending technology with human ingenuity, we look forward to helping Organon embrace the power of change to create holistic value to drive growth."

Organon to Acquire Forendo Pharma

Retrieved on: 
Thursday, November 11, 2021
Baby, Maternity, Pharmaceutical, Health, Consumer, MSD, Achievement, Science, Private Securities Litigation Reform Act, News, Intracrine, Tissue, Novartis, Health, OGN, Endometriosis, PCOS, Disease, Patent, CEO, Security (finance), Failure, Seed, MRK, Investment, Infertility, COVID-19, Multimedia, Lists of diseases, Forward-looking statement, Lead, Woman, Acquisition, Chronic liver disease, U.S. Securities and Exchange Commission, Hyperandrogenism, SEC, NYSE, HSD17B, Review, Hart–Scott–Rodino Antitrust Improvements Act, Physician, HSD17B1, Anovulation, Abdominal pain, Patient, Risk, Form 10-K, Pharmaceutical industry, Risk management, Organon, Forendo, ORGANON, FORENDO

Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in womens health.

Key Points: 
  • Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in womens health.
  • Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach.
  • Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.
  • In addition to womens health programs, Forendo has a strategic collaboration with Novartis leveraging its unique HSD17B platform in chronic liver diseases.

NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary

Retrieved on: 
Monday, November 8, 2021
MSD, Coronavirus, Private Securities Litigation Reform Act, Pregnancy, News, Health, Health Canada, OGN, Method, Security (finance), Arm, MRK, STI, Veterans Affairs Canada, Investment, Internal bleeding, COVID-19, Condom, MRI, USS, Woman, U.S. Securities and Exchange Commission, Magnetic resonance imaging, SEC, NYSE, Physician, Subdermal implant, Patient, CT, Patent, RAMQ, Non-Insured Health Benefits, Birth control, Pharmaceutical industry

KIRKLAND, QC, Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to announce NEXPLANON (etonogestrel extended-release subdermal implant) public listing in Quebec under the Rgie de l'assurance maladie du Qubec (RAMQ) as of November 10.

Key Points: 
  • KIRKLAND, QC, Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to announce NEXPLANON (etonogestrel extended-release subdermal implant) public listing in Quebec under the Rgie de l'assurance maladie du Qubec (RAMQ) as of November 10.
  • NEXPLANON is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1Quebec is the fifth jurisdiction to list NEXPLANON on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.
  • "Choosing a contraception method is an incredibly personal decision based on what's best for your body and your needs.
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

Retrieved on: 
Thursday, November 4, 2021
Woman, Pregnancy, Fertilisation, SIX Swiss Exchange, JGB, Gonadotropin-releasing hormone, Drug development, European Medicines Agency, New Drug Application, EMA, Security (finance), Patient, Private Securities Litigation Reform Act, NASDAQ, Investor, FDA, NYSE, SEC, Risk, Dysmenorrhea, Uterine fibroid, Income, CHMP, Marketing, Company, EDELWEISS, Nasdaq, CEO, NETA, U.S. Securities and Exchange Commission, Linzagolix, Birth certificate, Endometriosis, Research, OGN, Commercial, ABT, Syneos Health, Treatment, Coronavirus, Hormone, Cryptocurrency, Animal, Pharmaceutical industry, Birth control, Online shopping

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland November 4, 2021 ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today reported financial results for the quarter ended September 30, 2021 and provided a business update.
  • As of September 30, 2021, ObsEva had cash and cash equivalents of $62.9 million, compared with $31.2 million as of December 31, 2020.
  • The third quarter 2021 financial report will be available in the financial reports section of the Companys website.
  • To access the third quarter 2021 financial report directly, please click [ h e re ].